Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Fujifilm Cellular Dynamics Inc. is actively prosecuting 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. This level of activity reflects a significant commitment to securing intellectual property in a highly technical field. The 7 pending matters represent the current front line of the company's efforts to expand its biological and pharmaceutical patent holdings.
The prosecution landscape for this portfolio is notably diverse, featuring 7 distinct examiners across 5 distinct art units. Because there are 7 examiners for the active actions, each matter is being reviewed by a different individual, preventing any single examiner from having an outsized impact on the portfolio. However, the concentration in 5 art units suggests that while the examiners differ, the technological focus remains within a narrow set of USPTO classifications.
BERTOGLIO, VALARIE E is the busiest examiner currently assigned to the portfolio, with 1 busiest examiner pending office action. Although this examiner is the busiest, they only manage 1 of the 7 total actions, indicating an even distribution of work across the USPTO staff. This lack of concentration means that the company must adapt to the unique requirements of many different examiners rather than focusing on the tendencies of a single primary reviewer in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §103 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.3% |
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
| SUNG, GERALD LUTHER | 1 | 79.9% | +28.6% |
| STAVROU, CONSTANTINA E | 1 | 42.4% | +35.6% |
| NOBLE, MARCIA STEPHENS | 1 | 67.2% | +39.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18886115 | MACS-BASED PURIFICATION OF STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM | BERTOGLIO, VALARIE E | — |
| 18824380 | METHOD FOR DIFFERENTIATION OF OCULAR CELLS AND USE THEREOF | SPENCE, JENNIFER SUZANNE | — |
| 18479052 | APPARATUS AND METHODS FOR DELIVERY OF CELL COMPOSITIONS | SUNG, GERALD LUTHER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18886115 | MACS-BASED PURIFICATION OF STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM | BERTOGLIO, VALARIE E | — |
| 18824380 | METHOD FOR DIFFERENTIATION OF OCULAR CELLS AND USE THEREOF | SPENCE, JENNIFER SUZANNE | — |
| 18769320 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | KIM, TAEYOON | — |
| 18554103 | DOPAMINERGIC PRECURSOR CELLS AND METHODS OF USE | NGUYEN, NGHI V | — |
| 18479052 | APPARATUS AND METHODS FOR DELIVERY OF CELL COMPOSITIONS | SUNG, GERALD LUTHER | — |
| 17931440 | COMPOSITIONS OF INDUCED PLURIPOTENT STEM CELL-DERIVED CELLS AND METHODS OF USE THEREOF | STAVROU, CONSTANTINA E | — |
| 16782772 | METHODS FOR DIFFERENTIATING PLURIPOTENT CELLS | NOBLE, MARCIA STEPHENS | — |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1633 | 1 |
| 1631 | 1 |
| 1653 | 1 |
| 3741 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18886115 | MACS-BASED PURIFICATION OF STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM | BERTOGLIO, VALARIE E | — | §101§102§112Other | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18824380 | METHOD FOR DIFFERENTIATION OF OCULAR CELLS AND USE THEREOF | SPENCE, JENNIFER SUZANNE | 1633 | §101§102§103DP | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18769320 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | KIM, TAEYOON | 1631 | §102§103§112DP | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18554103 | DOPAMINERGIC PRECURSOR CELLS AND METHODS OF USE | NGUYEN, NGHI V | 1653 | §102§112DP | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18479052 | APPARATUS AND METHODS FOR DELIVERY OF CELL COMPOSITIONS | SUNG, GERALD LUTHER | 3741 | §102§103§112 | Non-Final OA | — | Pending | Sep 30, 2023 |
| 17931440 | COMPOSITIONS OF INDUCED PLURIPOTENT STEM CELL-DERIVED CELLS AND METHODS OF USE THEREOF | STAVROU, CONSTANTINA E | 1632 | §103 | Final Rejection | — | Pending | Sep 12, 2022 |
| 16782772 | METHODS FOR DIFFERENTIATING PLURIPOTENT CELLS | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | — | Pending | Feb 05, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFujifilm Cellular Dynamics Inc. has 7 pending office actions as of October 2026, spread across 5 art units and 7 examiners.
Valarie E Bertoglio has the most, with 1 of Fujifilm Cellular Dynamics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
